Dr. George Coukos is the director of the Department of Oncology at the University Hospitals of Canton Vaud (CHUV), the director of the service of developmental therapeutics, and the director of the Ludwig Centre at the University of Lausanne.
Dr. Coukos is a globally recognized leader in ovarian cancer immunotherapy with extensive experience in designing and conducting immunotherapy clinical trials. He previously revealed the existence of spontaneous immune responses in ovarian tumors as well as described how regulatory T cells and tumor blood vessels affect these responses. In addition to being a member of CRI’s Clinical Leadership Committee, Dr. Coukos is currently the lead investigator of a CRI-funded clinical trial that is treating ovarian cancer patients with two immunotherapies―MEDI4736, an anti-PD-L1 checkpoint inhibitor, and motolimod, a TLR8 agonist.
[Immunotherapy] makes it possible to act even in cases that were previously considered hopeless. To have patients in remission for more than five years after diagnosis is truly a miracle.
Let's spread the word about Immunotherapy! Click to share this page with your community.